WESTMINSTER, Colo.--(BUSINESS WIRE)--May. 12, 2009--
Allos Therapeutics, Inc. (NASDAQ:ALTH), a biopharmaceutical company
focused on developing and commercializing innovative small molecule
drugs for the treatment of cancer, today announced that members of the
Company’s senior management will present on Tuesday, May 19, at 12:00
p.m. Pacific Time at the Eighth Annual JMP Securities Research
Conference taking place at the Ritz-Carlton in San Francisco.
There will be a live webcast of the presentation, which will be
accessible through a link posted on the home page and investor relations
section of the Allos website. The webcast will be available for replay
through May 29, 2009.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on developing
and commercializing innovative small molecule drugs for the treatment of
cancer. The Company’s product candidate, pralatrexate, is a targeted
antifolate designed to accumulate preferentially in cancer cells. In
February 2009, the Company announced the final results from PROPEL, the
Company’s pivotal Phase 2 trial of pralatrexate in patients with
relapsed or refractory peripheral T-cell lymphoma (PTCL). The PROPEL
trial was conducted under an agreement reached with the U.S. Food and
Drug Administration under its special protocol assessment (SPA) process.
Based on the results of the PROPEL trial, the Company submitted a New
Drug Application to the U.S. Food and Drug Administration for
pralatrexate for the treatment of relapsed or refractory PTCL in March
2009. The Company is also investigating pralatrexate in patients with
non-small cell lung cancer, bladder cancer and a range of lymphoma
sub-types. The Company currently retains exclusive worldwide rights to
pralatrexate for all indications. For additional information, please
visit www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements
that involve significant risks and uncertainties. Additional information
concerning these forward-looking statements and other factors that may
cause actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Quarterly Report on Form 10-Q for the quarter ended March
31, 2009 and in the Company's other periodic reports and filings with
the Securities and Exchange Commission. The Company cautions investors
not to place undue reliance on the forward-looking statements contained
in the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof, and
the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the
date of this presentation, except as required by law.
Source: Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
Monique Greer, 303-426-6262
mgreer@allos.com
